Literature DB >> 7865351

Cytokines in the treatment of fungal infections.

B J Kullberg1, J W van 't Wout.   

Abstract

The incidence of invasive fungal infections in the immunocompromized host has increased during the past decade. Even the recently developed antifungal drugs are unable to cure these infections in patients with severely impaired host defense mechanisms. Cytokines have great potential to augment host resistance and as adjunctive therapy of invasive mycoses. We discuss the mechanisms of host defense against invasive candidiasis, aspergillosis, and cryptococcosis, and review the use of cytokines and growth factors in this setting. Interleukin-1 has been shown effective in an animal model of disseminated candidiasis, even during severe granulocytopenia. Interferon-gamma has been very effective as a modulator of resistance against a variety of fungal infections in vitro. The effect of interferon-gamma against disseminated candidiasis has been demonstrated in a mouse model. Activation of neutrophils is the main mechanism by which interferon-gamma enhances the elimination of Candida, and consequently the agent is not effective in severely granulocytopenic animals. Data on the role of colony-stimulating factors against fungal pathogens are accumulating, and trials with these agents for hematologic patients with invasive fungal infections are now being performed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865351     DOI: 10.1007/bf01878486

Source DB:  PubMed          Journal:  Biotherapy        ISSN: 0921-299X


  3 in total

1.  Gamma interferon protects endothelial cells from damage by Candida albicans by inhibiting endothelial cell phagocytosis.

Authors:  R A Fratti; M A Ghannoum; J E Edwards; S G Filler
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 2.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 3.  Trends in immunotherapy of fungal infections.

Authors:  B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.